Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2014 05:44 ET | Source: Bionor Pharma

UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV

OSLO, NORWAY--(Marketwired - Nov 18, 2014) - Bionor Pharma ASA (OSLO: BIONOR) Treatment with Vacc-4x + Revlimid (lenalidomide) was well tolerated ...
November 17, 2014 08:01 ET | Source: Bionor Pharma

Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV

OSLO, NORWAY--(Marketwired - Nov 17, 2014) - Bionor Pharma ASA (OSLO: BIONOR) Treatment with Vacc-4x + Revlimid (lenalidomide) was safe and well tolerated ...
February 11, 2014 09:27 ET | Source: Bionor Pharma

Bionor Pharma's Phase II Vacc-4x Data Published in the Lancet Infectious Diseases

OSLO, NORWAY--(Marketwired - Feb 11, 2014) - Bionor Pharma ASA (OSE: BIONOR) announces that the results from the randomized, multicenter, double-blinded, placebo-controlled Phase II trial with 135...
June 07, 2012 07:01 ET | Source: Bionor Pharma

International Patent Application Submitted for the Therapeutic and Potentially Preventive Vaccine Vacc-HIV, Combining Bionor's Vacc-4x and Vacc-C5

OSLO, NORWAY--(Marketwire - Jun 7, 2012) - Bionor Pharma ASA (OSLO: BIONOR) announced today that it has initiated the international patent process for protection of the Company's peptide vaccine...
June 07, 2012 07:00 ET | Source: Bionor Pharma

International Patent Application Submitted Covering Vaccines for Influenza (Universal Vaccine), Hepatitis C, Cytomegalovirus and Human Papillomavirus

OSLO, NORWAY--(Marketwire - Jun 7, 2012) - Bionor Pharma ASA (OSLO: BIONOR) News Summary The new patent filed 6 June aims to strengthen the Company's general protection of its...
May 29, 2012 11:22 ET | Source: Bionor Pharma

First Human Clinical Study of HIV Vaccine Vacc-C5 Approved to Begin

OSLO, NORWAY--(Marketwire - May 29, 2012) - Bionor Pharma ASA (OSLO: BIONOR) News Summary Open, clinical study, dose escalating, phase I/II, with Bionor...
May 11, 2012 08:52 ET | Source: Bionor Pharma

Bionor Pharma's Shareholders Voted Industry Experts Steen Kroyer, Jerry Zeldis and Benedicte Fossum to Its Board of Directors at Annual General Meeting

OSLO, NORWAY--(Marketwire - May 11, 2012) - Bionor Pharma ASA (OSLO: BIONOR) announced today unanimously shareholder approval for new and re-elected Board members to the Board of Directors, and...
May 10, 2012 06:47 ET | Source: Bionor Pharma

Successful Immunization and Safety Documented in Nasal Administration Study of the HIV Vaccine Vacc-4x Together With Endocine

OSLO, NORWAY--(Marketwire - May 10, 2012) - Bionor Pharma (OSLO: BIONOR) News Summary Vaccine related immune responses found in HIV patients given Vacc-4x...
February 15, 2012 08:00 ET | Source: Bionor Pharma

With Final Review of Phase IIb Viral Load Data Completed, Researchers Confirm Statistically Significant Reduction of HIV Viral Load on Vacc-4x Compared to Placebo

OSLO, NORWAY--(Marketwire - Feb 15, 2012) - Bionor Pharma (OSLO: BIONOR) News Summary Final review of phase IIb data confirms statistically significant 64%...
January 23, 2012 08:00 ET | Source: Bionor Pharma

With Final Documentation Submitted for International Patent Applications, Bionor Sees Promise of Two Core Platform Technologies

OSLO, NORWAY--(Marketwire - Jan 23, 2012) - News Summary Bionor Pharma ASA has previously submitted two international patent applications for the Company's...

Next Page keyboard_arrow_right